S100A4

S100A4, also known as S100 calcium-binding protein A4, is a member of the S100 protein family encoded by the S100A4 gene. Commonly referred to as metastasin-1 (MTS1) or fibroblast-specific protein-1 (FSP1), this EF-hand calcium-binding protein regulates cellular processes including cytoskeletal dynamics, cell motility, and extracellular matrix remodeling. It exerts pleiotropic effects through interactions with intracellular targets like non-muscle myosin heavy chain and extracellular receptors such as RAGE (receptor for advanced glycation end-products), activating pathways including MAPK, NF-κB, and Wnt/β-catenin signaling. Its activity is closely associated with epithelial-mesenchymal transition (EMT), a key mechanism in cancer progression and fibrosis development.
Elevated S100A4 expression correlates with metastatic potential in various cancers, particularly breast, colorectal, and pancreatic carcinomas. It also contributes to fibrotic disorders such as pulmonary fibrosis and rheumatoid arthritis. Therapeutic strategies targeting S100A4 include small-molecule inhibitors disrupting its dimerization and monoclonal antibodies blocking extracellular functions. Preclinical studies demonstrate reduced metastasis and fibrosis in animal models, though no clinical-stage compounds have been reported. Recent efforts focus on identifying allosteric inhibitors and exploring combination therapies with conventional chemotherapeutic agents to counteract treatment resistance.